Aldeyra Therapeutics, Inc. (ALDX) To File FDA FDRR on Reproxalap; Cash Runway Into 2029

Aldeyra plans an FDA Formal Dispute Resolution Request for reproxalap after a March 16, 2026 CRL, with OND meeting expected in Q4 2026. The company also guided operational cash runway into 2029.Material DetailsContext by AI AnalystThis is a regulatory appeal after multiple CRLs for reproxalap, sign…